Measurable residual disease testing in acute myeloid leukaemia

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group

(2017) Marie Balsat et al.   JOURNAL OF CLINICAL ONCOLOGY

Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?

(2017) Farhad Ravandi et al.   Journal of the National Comprehensive Cancer Network

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

(2016) Matthew P. Mulé et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

(2016) Delphine Rea et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study

(2016) Anne Tierens et al.   BRITISH JOURNAL OF HAEMATOLOGY

Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI

(2016) M. Othus et al.   HAEMATOLOGICA

When the Minimal Becomes Measurable

(2016) Christopher S. Hourigan et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease–Based Definition of Complete Remission?

(2016) Daisuke Araki et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

(2016) M Othus et al.   LEUKEMIA

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

(2016) V S Hoffmann et al.   LEUKEMIA

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

(2016) A Hochhaus et al.   LEUKEMIA

Pre- and post-transplant quantification of measurable (‘minimal’) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia

(2016) Y Zhou et al.   LEUKEMIA

The concept of treatment-free remission in chronic myeloid leukemia

(2016) S Saußele et al.   LEUKEMIA

Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

(2016) María-Belén Vidriales et al.   LEUKEMIA RESEARCH

Precision medicine in acute myeloid leukemia: Hope, hype or both?

(2016) Vinay Prasad et al.   LEUKEMIA RESEARCH

Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

(2016) Sheng Li et al.   NATURE MEDICINE

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016)   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of Minimal Residual Disease in Standard-Risk AML

(2016) Adam Ivey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults

(2016) Andrew L. Young et al.   Nature Communications

Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI

(2016) M. Othus et al.   HAEMATOLOGICA

Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium

(2016) Greg Finak et al.   Scientific Reports

Is Having Clonal Cytogenetic Abnormalities the Same as Having Leukaemia?

(2015) Mirko Farina et al.   ACTA HAEMATOLOGICA

Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms: A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program

(2015) Michael Keeney et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML

(2015) T. N. Wong et al.   BLOOD

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance

(2015) D. Grimwade et al.   BLOOD

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

(2015) D. P. Steensma et al.   BLOOD

A multigene array for measurable residual disease detection in AML patients undergoing SCT

(2015) M Goswami et al.   BONE MARROW TRANSPLANTATION

Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry

(2015) Brent L. Wood   CYTOMETRY PART B-CLINICAL CYTOMETRY

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

(2015) C. Willekens et al.   HAEMATOLOGICA

The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes

(2015) E. J. Duncavage et al.   International Journal of Laboratory Hematology

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

(2015) Jeffery M. Klco et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Role of Physicians in the Era of Predictive Analytics

(2015) Allan D. Sniderman et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia

(2015) Xueyan Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Reply to D. Przepiorka et al

(2015) Xueyan Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study

(2015) Ching-Hon Pui et al.   LANCET ONCOLOGY

New drug approvals in acute myeloid leukemia: what’s the best end point?

(2015) E Estey et al.   LEUKEMIA

Quantifying ultra-rare pre-leukemic clones via targeted error-corrected sequencing

(2015) A L Young et al.   LEUKEMIA

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

(2015) N C P Cross et al.   LEUKEMIA

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia

(2015) Peter Hokland et al.   SEMINARS IN HEMATOLOGY

Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial

(2015) C. Willekens et al.   HAEMATOLOGICA

Optimizing Cancer Genome Sequencing and Analysis

(2015) Malachi Griffith et al.   Cell Systems

Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?

(2014) David Grimwade et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Isolated Clonal Cytogenetic Abnormalities after High-Dose Therapy

(2014) Margaret M. Showel et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

(2014) D. Grimwade et al.   BLOOD

Measureable residual disease (MRD): much ado about nothing?

(2014) R P Gale   BONE MARROW TRANSPLANTATION

Relapse kinetics in acute myeloid leukaemias withMLLtranslocations or partial tandem duplications within theMLLgene

(2014) Hans B. Ommen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Persistence ofDNMT3Amutations at long-term remission in adult patients with AML

(2014) Gro G. Pløen et al.   BRITISH JOURNAL OF HAEMATOLOGY

Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia

(2014) Jeffery M. Klco et al.   CANCER CELL

Prospective Validation of a New Method of Monitoring Minimal Residual Disease in Childhood Acute Myelogenous Leukemia

(2014) D. Steinbach et al.   CLINICAL CANCER RESEARCH

Quality assessment program for EuroFlow protocols: Summary results of four-year (2010-2013) quality assurance rounds

(2014) Tomas Kalina et al.   CYTOMETRY PART A

ICSH: on board for new projects

(2014) G. Zini et al.   International Journal of Laboratory Hematology

Outcomes of Children With BCR-ABL1–Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease

(2014) Kathryn G. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial

(2014) Ajay Vora et al.   LANCET ONCOLOGY

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

(2014) B Hanfstein et al.   LEUKEMIA

Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence

(2014) Giulio Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes

(2014) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

(2014) M. R. Corces-Zimmerman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Concise Reviews: A Stem Cell Apostasy: A Tale of Four H Words

(2014) Peter J. Quesenberry et al.   STEM CELLS

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

(2013) A. Flanders et al.   BLOOD

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

(2013) N. Shayegi et al.   BLOOD

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

(2013) E. Jourdan et al.   BLOOD

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

(2013) H.-H. Zhu et al.   BLOOD

Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation

(2013) Dario Campana et al.   BRITISH JOURNAL OF HAEMATOLOGY

Tumor heterogeneity makes AML a “moving target” for detection of residual disease

(2013) W. Zeijlemaker et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia

(2013) Sylvie D. Freeman et al.   JOURNAL OF CLINICAL ONCOLOGY

Use of Allogeneic Hematopoietic Stem-Cell Transplantation Based on Minimal Residual Disease Response Improves Outcomes for Children With Relapsed Acute Lymphoblastic Leukemia in the Intermediate-Risk Group

(2013) Cornelia Eckert et al.   JOURNAL OF CLINICAL ONCOLOGY

Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission

(2013) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

(2013) Monique Terwijn et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial

(2013) Ajay Vora et al.   LANCET ONCOLOGY

What does MRD in leukemia really mean?

(2013) J M Goldman et al.   LEUKEMIA

Bone marrow WT1 levels at diagnosis, post-induction and post-intensification in adult de novo AML

(2013) J F Nomdedéu et al.   LEUKEMIA

Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia

(2013) Carlo Marani et al.   LEUKEMIA RESEARCH

Minimal residual disease in acute myeloid leukaemia

(2013) Christopher S. Hourigan et al.   Nature Reviews Clinical Oncology

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group

(2012) M. R. Loken et al.   BLOOD

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

(2012) J. A. L. Yin et al.   BLOOD

Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia

(2012) S A Buckley et al.   BONE MARROW TRANSPLANTATION

The Origin and Evolution of Mutations in Acute Myeloid Leukemia

(2012) John S. Welch et al.   CELL

Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia

(2012) Hiroto Inaba et al.   JOURNAL OF CLINICAL ONCOLOGY

Minimal Residual Disease–Guided Treatment Deintensification for Children With Acute Lymphoblastic Leukemia: Results From the Malaysia-Singapore Acute Lymphoblastic Leukemia 2003 Study

(2012) Allen Eng Juh Yeoh et al.   JOURNAL OF CLINICAL ONCOLOGY

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

Standardized definitions of molecular response in chronic myeloid leukemia

(2012) N C P Cross et al.   LEUKEMIA

EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols

(2012) T Kalina et al.   LEUKEMIA

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

(2012) Li Ding et al.   NATURE

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia

(2011) F. Buccisano et al.   BLOOD

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia

(2011) Letizia Foroni et al.   BRITISH JOURNAL OF HAEMATOLOGY

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

(2011) K. Sockel et al.   HAEMATOLOGICA

Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group

(2011) Jan Krönke et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Common Leukemia- and Lymphoma-Associated Genetic Aberrations in Healthy Individuals

(2011) Jianbo Song et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet

(2011) M Østergaard et al.   LEUKEMIA

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

(2011) U Platzbecker et al.   LEUKEMIA

Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm

(2010) R. B. Walter et al.   BLOOD

Towards individualized follow-up in adult acute myeloid leukemia in remission

(2010) P. Hokland et al.   BLOOD

Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia

(2010) F. Buccisano et al.   BLOOD

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial

(2010) Jeffrey E Rubnitz et al.   LANCET ONCOLOGY

Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias

(2009) H. B. Ommen et al.   BLOOD

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

(2009) A. A. van de Loosdrecht et al.   HAEMATOLOGICA

Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by StandardizedWT1Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

(2009) Daniela Cilloni et al.   JOURNAL OF CLINICAL ONCOLOGY

Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia

(2008) Luca Maurillo et al.   JOURNAL OF CLINICAL ONCOLOGY